South Dakota MPJE Pharmacy Law Study Guide

1. Initial pharmacist licensure

Initial licensure is a sequence of conditions, not a single event. In a South Dakota case, identify the education, examination, application, and other requirements the governing provision actually states. Then separate evidence that the applicant meets those requirements from the board's decision to issue a license. A passing score or completed application can establish eligibility without creating authority to practice. Check the credential's effective date and status before assigning work reserved to a pharmacist. If the person also holds an intern credential, analyze any proposed intern activity under that credential's separate limits and supervision conditions. Do not assume pharmacist authority simply because the person has graduated. On a date-sensitive question, put completion, approval, issuance, and the proposed service in chronological order. The decisive question is whether an effective pharmacist license covered the service when it occurred.

Worked example: A graduate completes every condition in a hypothetical South Dakota initial-licensure rule on August 5. The board receives the last document that day but issues a license effective August 8. On August 7, the graduate is eligible for approval but cannot independently verify prescriptions as a licensed pharmacist. An intern credential, if held, would permit only the activities and supervision allowed under its own terms.

Watch the distinction: Completing the last requirement does not automatically activate a license. Eligibility supports an application; pharmacist practice requires an effective credential covering the date and activity.

2. Licensure by transfer

Licensure by transfer starts with an existing license but still requires a distinct South Dakota authorization. First confirm the other license is current and unrestricted if the supplied transfer rule requires those facts. Next identify every South Dakota condition, such as an application, state-law examination, or board approval. Finally check the South Dakota license's effective status before practice begins. A transfer process may recognize prior qualifications without importing another state's practice authority across the border. Separate the source license's standing from the receiving state's decision: a disciplinary restriction in the source state may affect eligibility, while a clean source license still does not complete the South Dakota process. In a selected-response case, the safest sequence is source credential, transfer conditions, board action, then service date. The MPJE study guide can help you practice that order across jurisdictions.

Worked example: A Minnesota pharmacist has an unrestricted license and submits a South Dakota transfer application on March 1. A hypothetical South Dakota provision also requires a state-law examination and board approval. The pharmacist passes the examination on March 10, but approval occurs March 15. Minnesota licensure supports transfer eligibility; it does not authorize independent South Dakota pharmacist work on March 12.

Watch the distinction: An unrestricted license elsewhere establishes a relevant qualification, not automatic authority in South Dakota. Check the receiving state's remaining conditions and the effective date of its license.

3. Expired licenses and reinstatement

Renewal and reinstatement answer different timing problems. A timely renewal maintains authority when the governing rule says the credential continues; reinstatement addresses a license that has already expired. For a lapse, mark the expiration date, each service date, the application date, and the effective date of any restored authority. A later approval ordinarily does not change the historical status of work done during the gap unless an express provision gives it that effect. Also distinguish filing an application from having it granted. A case may attach extra education, fees, examination, or supervision conditions to reinstatement; apply only those supplied. If a grace or continuation rule appears, read exactly which activities and dates it covers. This chronology prevents a common error: deciding whether past work was authorized by looking only at the pharmacist's current status.

Worked example: A hypothetical license expires at the end of June 30. The pharmacist verifies prescriptions on July 2, applies for reinstatement July 3, and receives an effective reinstatement July 9. With no stated continuation or retroactive rule, July 2 falls in the expired period. The July 9 approval permits future practice but does not authorize the earlier verification.

Watch the distinction: Reinstatement is not a time machine. Unless the supplied law preserves or restores authority for the gap, work done while the license was expired remains unauthorized.

4. Credential status at the time of service

Credential status must be tested at the moment of the professional act. Build a short timeline containing the start and end of any suspension, restriction, expiration, or restoration, then place the service on it. The person may be fully qualified before and after a suspension yet lack authority during it. Read restrictions as carefully as outright suspensions: a limited license might permit some acts but exclude others. If a case gives an order date and a different effective date, use the date the order says the change takes effect. Record review dates, claim adjudication dates, and the date a complaint is investigated do not replace the service date. This same method applies to initial licenses, transfer approvals, renewals, and reinstatements. For each act, ask which credential existed, what activity it covered, and whether it was effective then.

Worked example: A pharmacist's suspension takes effect Monday at 9 a.m. and is lifted Friday at noon. The pharmacist verifies a prescription Thursday afternoon. Thursday lies inside the suspension, so that verification was outside the pharmacist's authority. A review conducted the following Tuesday, when the license is active, does not alter the status on Thursday.

Watch the distinction: Current license status cannot establish past authority. The controlling facts are the status, any restrictions, and their effective times when the service occurred.

5. Intern activities

Intern registration, task permission, and supervision are separate questions. Start with whether the person holds the intern credential required by the case. Then determine whether the particular act, such as counseling, data gathering, or preparation, falls within the intern's permitted activities. Finally compare the actual staffing arrangement with the rule's supervision language. Direct supervision, physical presence, and general availability can impose different conditions, so use the wording supplied rather than treating them as interchangeable. The supervising pharmacist's authority also matters: supervision by someone who cannot lawfully perform the act does not cure the problem. When an intern encounters a patient issue requiring independent clinical judgment, identify whether the governing rule reserves the decision to a pharmacist. Registration creates a pathway to supervised practice; it does not turn every pharmacy task into an independently permitted intern act.

Worked example: A hypothetical South Dakota provision allows a registered intern to counsel while directly supervised by an on-site pharmacist. An intern is registered and has prepared accurate counseling points, but the pharmacist leaves before the patient arrives. The registration and preparation satisfy two relevant facts; the required supervision is absent. The intern waits for an authorized pharmacist or uses another arrangement the rule permits.

Watch the distinction: An intern credential does not remove task limits or supervision conditions. Check all three elements before concluding that the intern may serve the patient.

6. Technician credentials and tasks

Delegation depends on both the task and the worker's credential. Prescription data entry may be a technical step, but a rule can still require technician registration before an employee performs it. Determine whether the credential must be issued, merely applied for, or held in a particular status; the case provision controls. Training, experience, and a supervisor's confidence do not replace a required registration. After checking credential status, decide whether the task itself is delegable and what pharmacist supervision and final verification it needs. A technician's accurate entry does not make the prescription clinically appropriate, and a pharmacist's later check does not automatically legalize an unauthorized earlier step. In a workflow question, identify each actor and time: who entered the data, who assessed clinical issues, who verified the finished prescription, and what credentials and supervision existed at those points.

Worked example: An employee completes pharmacy training on Monday and applies for a technician registration Tuesday. The hypothetical rule requires an issued registration for prescription entry. On Wednesday, while the application is pending, the employee enters ten orders. The training does not meet the credential condition. Future entry can begin only when the required credential is effective and the task's supervision conditions are met.

Watch the distinction: A technical task is not automatically open to any trained employee. A credential condition applies before delegation, and later pharmacist verification does not erase an earlier unauthorized act.

7. Clinical judgment and delegation

A technician can gather information, prepare a product, enter data, and flag a concern when the applicable rule permits those tasks. The pharmacist makes the clinical decision whether a regimen is appropriate and whether to dispense, clarify, change course, or refuse. The boundary appears when a fact needs interpretation: duplicate active therapies might represent an accidental double dose, a planned switch, or intentional combination treatment. Identifying the duplicate is useful technical work; deciding its meaning requires patient context and professional judgment. A pharmacist should examine the medication history, directions, timing, and any prescriber note, then resolve uncertainty with the prescriber when needed. Document the decision and update the record so a later refill does not recreate the same ambiguity. Delegation can move information through a workflow, but responsibility for the clinical conclusion remains with the authorized professional.

Worked example: A technician sees two active prescriptions for the same ingredient, one under a brand name and one generic. The technician flags both and pauses preparation. The pharmacist confirms with the prescriber that the generic replaces the brand, marks the older therapy discontinued, and then verifies the new dispense. The technician supplied the cue; the pharmacist resolved its clinical meaning.

Watch the distinction: Spotting a duplicate is different from deciding it is safe. A technician's flag should trigger pharmacist review rather than become an independent approval or rejection.

8. Supervision in a workflow

Supervision is a condition of a specific delegated act, not a general promise that a pharmacist can eventually be contacted. Read the supplied requirement closely: it may demand physical presence, immediate availability, direct observation, or another defined relationship. Then reconstruct the actual workflow, including who was on site, response time, and whether the delegated work continued while supervision was unavailable. A remote pharmacist might satisfy a rule expressly allowing remote supervision, but a phone number alone does not satisfy a rule requiring immediate availability. Also separate supervision of preparation from final pharmacist verification; meeting one condition does not necessarily meet the other. If staffing changes midshift, reassess the task at that point rather than assuming an earlier compliant arrangement continues. The practical decision is whether the work can proceed under the current arrangement or must pause until lawful coverage exists.

Worked example: A hypothetical rule requires a pharmacist to be immediately available while a technician prepares prescriptions. The pharmacist leaves the site and returns calls about an hour later. During that hour the technician begins three preparations. An hour-long response does not meet the stated immediate-availability condition, so the work must pause until qualifying supervision is restored.

Watch the distinction: Being reachable eventually is not the same as meeting a specified supervision standard. Compare the rule's exact condition with the staffing that existed during the task.

9. Pharmacist-in-charge authority

The pharmacist-in-charge, or PIC, has operational responsibility for systems such as staffing, procedures, record controls, and responses to known failures under the applicable provisions. That role does not absorb every individual pharmacist's duty at the point of care. Analyze two layers when something goes wrong. At the system layer, ask whether the PIC established and maintained a workable process, trained staff, and addressed recurring defects. At the transaction layer, ask what the dispensing pharmacist knew and did before release. A good procedure cannot turn a knowingly unverified dispense into an authorized one. Conversely, an individual error does not automatically prove the PIC failed; examine whether warning signs or control weaknesses were present. This division matters in cases asking who should act now: the dispensing pharmacist resolves the immediate prescription, while the PIC may need to correct the broader workflow.

Worked example: A PIC writes a procedure requiring pharmacist verification before release and trains the staff. Another pharmacist knowingly bypasses verification on one prescription and releases it. The release is that pharmacist's decision and must be addressed. The PIC should assess whether the bypass exposes a system weakness, but the existence of a compliant written procedure does not excuse the release.

Watch the distinction: PIC oversight is not a shield for another pharmacist's own acts. Assess the immediate professional decision and the operational controls as distinct responsibilities.

10. Staffing and oversight by the pharmacist-in-charge

Repeated supervision failures signal a control problem. Start by grouping events by shift, staffing level, task, and absence of the required pharmacist. A single technician error may call for correction and coaching; a pattern across shifts asks whether scheduling, training, assignment, or monitoring makes compliant work possible. The PIC should stop the unsafe workflow, arrange lawful coverage, identify the cause, and document corrective action and follow-up. Documentation should show what was found and what changed, not merely state that staff were reminded. The analysis should still identify individual acts: a technician who worked outside the permitted arrangement and a pharmacist who knowingly allowed it may have separate responsibilities. In a case, choose a response that controls future recurrence as well as addressing completed transactions, especially where prescriptions may have been prepared or released without required review.

Worked example: Records show technicians prepared prescriptions without required on-site pharmacist supervision on three shifts: Monday, Wednesday, and Friday. The PIC finds the schedule leaves a thirty-minute coverage gap each day. The PIC stops preparation during that gap, changes coverage, reviews affected work, and records the findings and follow-up. Three similar events point to a staffing control failure.

Watch the distinction: Calling every repeat event an isolated technician mistake misses the scheduling cause. A PIC must address a recurring system condition and document whether the correction worked.

11. Changes in pharmacist-in-charge

A PIC change can create two independent duties: continuous assignment of a qualified person and notice to the board or other authority. Read the case provision for when a change becomes effective, who must give notice, and what information it requires. Then build a timeline showing the outgoing PIC's last day, the successor's effective designation, and the notice date. A new PIC named later may end a vacancy but does not erase an earlier gap. Likewise, a successor on duty does not necessarily satisfy a separate reporting obligation. A practical handoff should account for controlled stock, pending discrepancies, records, staffing, and unresolved compliance issues, because responsibility cannot be transferred well through a name change alone. Avoid inventing a universal notice deadline; apply the deadline and counting convention actually supplied. The result should identify each missed condition separately.

Worked example: Under a hypothetical rule, a pharmacy must maintain an uninterrupted PIC designation and give notice when the change occurs. The outgoing PIC leaves May 1; a successor begins May 6; notice goes out May 7. May 1 through May 5 contain a five-day designation gap if the outgoing role ended at the start of May 1. The May 7 notice also misses the stated change-time requirement.

Watch the distinction: Naming a successor eventually does not cure an earlier gap. Designation and notice are separate conditions, so test the dates for each.

12. Continuing education and renewal

Continuing education questions require two counts: total qualifying hours and hours meeting any specified topic or format. First exclude activities that the supplied renewal rule does not recognize. Then add eligible hours, taking care not to double-count a course that appears in two records. Compare the total with the overall requirement and each subset with its own minimum. A surplus in a general category cannot automatically repair a shortage in a mandatory topic. Finally distinguish earning credit from proving it: a pharmacist may have completed a course yet lack the documentation the rule requires for renewal or audit. Check the relevant completion window and whether the credential remains effective while a deficiency is corrected. When numbers are given, show both calculations and the remaining shortfall. These steps keep a plausible total from hiding a narrower unmet condition.

Worked example: A hypothetical renewal rule requires 20 qualifying hours, including 2 hours on a specified topic. A pharmacist has 21 qualifying hours overall, but only 1 hour in that topic. The total exceeds the requirement by 1 hour: 21 minus 20 equals 1. The topic is short by 1 hour: 2 minus 1 equals 1. Renewal eligibility remains incomplete.

Watch the distinction: More total hours do not necessarily satisfy a required subset. Count the topic hours separately and verify that completed education has the required documentation.

13. Reporting credential changes

Reporting duties attach to a specified person, event, and trigger date. Read who must report: the individual pharmacist, the pharmacy, the PIC, or more than one of them. Next identify whether the clock starts with an order, notice, final disposition, discovery, or another event named in the rule. Use the supplied calendar-day or business-day method and any convention for counting the first day. Record the deadline and compare it with the actual submission date. A report's content may also matter; merely telling a coworker is not necessarily a report to the required authority. When another state's discipline is involved, do not assume it has already reached South Dakota through an information system. The legal question is whether the named reporter fulfilled the case provision by its deadline, while any effect on the pharmacist's status is a separate issue.

Worked example: A hypothetical provision gives a pharmacist 10 calendar days after another state's disciplinary order to report it, counting from the next day. The order is entered April 4. April 5 is day 1 and April 14 is day 10, so April 14 is the deadline. A report submitted April 16 is 2 calendar days late.

Watch the distinction: Do not count from when the pharmacist chooses to read the order if the rule starts at entry. Identify the stated trigger and counting method first.

14. Conduct supporting discipline

Disciplinary analysis should name the conduct supported by the facts rather than jump to a single label. Missing controlled stock may indicate diversion, theft, poor records, or a counting error; investigate its movement before concluding which occurred. A deliberately false adjustment is a separate integrity issue even if the inventory discrepancy is later explained. Impairment concerns ability to practice safely and calls for a response based on observed conduct and the governing provision, while unauthorized practice concerns credential or scope status. Deficient supervision may belong to the pharmacist who allowed an impermissible task or to operational oversight, depending on the case. Use records, witness accounts, transaction dates, and access logs to separate suspicion from proof. The DEA Diversion Control Division provides federal registration and diversion resources; it does not determine South Dakota disciplinary findings for a particular case.

Worked example: A pharmacist removes a bottle of controlled medication from stock without a patient dispense, then enters an adjustment saying the bottle was broken. No breakage record or witness supports that entry. The missing bottle warrants a diversion investigation. The knowingly false adjustment is separately relevant because it conceals stock movement, regardless of whether investigators ultimately prove where the bottle went.

Watch the distinction: An unexplained shortage is a warning, not proof of diversion. A knowingly false record can still be misconduct on its own facts.

Reference: [1]

15. Individual, facility, and DEA authority

Three permissions can be involved in one pharmacy transaction. The pharmacist's individual license authorizes professional practice within its scope. The state pharmacy permit authorizes the facility's activities at the covered premises. A federal DEA registration, when required, authorizes the registrant's controlled-substance activities within its terms. None automatically supplies either of the others. In a case, identify the actor, site, drug, and act, then match each required credential to that element. For ordinary prescriptions, a DEA registration may be irrelevant; for controlled stock, it becomes central. A newly issued state permit does not establish that federal registration is effective, and an individual pharmacist's license does not make an unregistered facility a lawful controlled-substance handler. Also check whether the prescription itself is valid and the prescriber has appropriate authority; facility credentials do not repair a defective order.

Worked example: A licensed pharmacist begins work at a new South Dakota pharmacy with an effective state permit. The case states that the facility needs DEA registration to order and dispense federally controlled substances, but its registration is still pending. It may perform activities covered by its state permit that do not require that registration. It cannot use the pharmacist's personal license to order or dispense controlled stock for the unregistered facility.

Watch the distinction: A person, premises, and federal registrant are different legal subjects. Confirm the credential required for each controlled-substance activity rather than treating one approval as universal.

Reference: [1]

16. Selecting the source of practice authority

Before providing a patient-care service, identify its legal source of authority. A pharmacist might act under independent statutory authority, a patient-specific prescription, a standing order or protocol, a collaborative agreement, or another instrument described in the case. Each source has its own conditions and scope. Ask who issued it, which medicines and patients it covers, what assessments are required, and whether the pharmacist may initiate, modify, administer, or only dispense. These verbs matter: authority to dispense a prescribed drug does not necessarily permit initiating therapy, and authority to administer does not necessarily permit prescribing. Check whether training, records, notification, or referral duties attach to the pathway. If one pathway fails, consider another only when the facts provide one. For South Dakota MPJE practice questions, trace authority from the proposed act back to the exact grant and its conditions.

Worked example: A walk-in patient requests a medicine that a hypothetical protocol lets pharmacists initiate only for patients meeting its screening criteria. The patient declines the required screening. The protocol therefore supplies no authority to initiate for this visit. A valid prescription from an authorized prescriber would be a different pathway, but none is present. The pharmacist addresses the patient's need through an appropriate referral.

Watch the distinction: Pharmacist involvement in a service does not itself establish prescribing authority. Match the exact proposed act and patient to a valid legal pathway.

17. Immunization authority

Immunization authority is usually conditional, so examine it as a checklist rather than relying on a general statement that pharmacists give vaccines. Under the provision supplied in a case, identify the authorized vaccine or category, patient eligibility, pharmacist training or credential, required prescription or protocol, and any record or communication duty. A patient who meets an age condition may still be outside the vaccine list; a listed vaccine may still be unavailable under the stated authority if the pharmacist lacks required training. Distinguish legal eligibility from clinical suitability. A patient may be legally eligible but need clinical assessment for contraindications or precautions, while a clinically sensible vaccine cannot be administered under a grant that excludes it. If a case includes multiple authorization sources, test each separately. End by stating the permitted action and what condition remains unmet, rather than assuming an exception.

Worked example: A hypothetical South Dakota provision lets trained pharmacists administer vaccines A and B to patients meeting its age condition. A trained pharmacist sees an age-eligible patient who requests vaccine C. Training and age are satisfied, but C is absent from the authorized list. The pharmacist cannot administer C under this provision and must identify another valid authorization route before doing so.

Watch the distinction: Meeting the patient age condition is only one part of authority. Check the vaccine, pharmacist qualifications, and the applicable order or protocol too.

18. Medication administration versus dispensing

Dispensing transfers a prepared and labeled medication to a patient or authorized recipient for later use. Administration is the act of giving a dose to the patient. The two acts can occur in one encounter but may require different legal authority, training, records, and consent. Begin with the prescription's intended act: an order for a patient to use an injectable medicine at home supports dispensing when otherwise valid; it does not automatically empower the pharmacist to inject it on site. Then read any South Dakota administration provision supplied in the case for covered drugs, patients, settings, and conditions. Also separate clinical tasks: counseling on injection technique is distinct from physically administering the dose. A case may permit one act and prohibit the other. The correct conclusion should state which service is authorized and identify the missing condition for the proposed additional act.

Worked example: A patient presents a valid prescription for an injectable medicine intended for home use. The case permits the pharmacy to dispense it but requires a separate authorization for pharmacist administration, which the pharmacist does not have. The pharmacist may dispense with appropriate counseling and records. Giving the first dose in the pharmacy would exceed the stated authority despite the valid prescription.

Watch the distinction: A prescription for an injectable product does not necessarily authorize the pharmacist to inject it. Dispensing and administration have separate legal and clinical conditions.

19. Collaborative practice limits

A collaborative practice agreement grants only the actions described within its boundaries. Read it in four passes: covered patients, covered medicines or conditions, permitted actions, and required procedures. Patient enrollment can be as decisive as a qualifying laboratory result. A pharmacist may be allowed to adjust a dose but not start a new medicine, or to act only after a specified test and notify the collaborating prescriber afterward. Check the agreement's effective period and whether the particular pharmacist is a participant when those facts are given. Documentation is part of the authorized workflow because it lets the care team see what changed and why. If a patient falls outside the agreement, the pharmacist can assess the issue and contact an authorized prescriber, but should not treat a clinically sensible adjustment as automatically authorized.

Worked example: An agreement permits dose changes for enrolled diabetes patients after a specified laboratory result. A patient's result meets the criterion, but the enrollment list does not include that patient. One condition is met and one is not, so the agreement does not authorize a dose change. The pharmacist can communicate the result and a recommendation to the patient's prescriber for a separate decision.

Watch the distinction: A qualifying clinical result does not expand an agreement's patient scope. Verify enrollment and the permitted action before making or documenting a medication change.

20. Pharmacist prescribing conditions

Pharmacist prescribing under a stated grant is a decision pathway, not simply permission to issue an order. First confirm the medicine, patient, setting, and pharmacist meet the grant's eligibility conditions. Perform each required assessment, using the actual answers rather than assuming a normal screen. Next apply exclusion and referral triggers. A warning symptom can terminate the prescribing pathway even when the patient otherwise seems eligible. If prescribing remains authorized, select the treatment within the allowed options and complete the required prescription, patient instructions, records, and any notice to another clinician. If the pathway ends in referral, document the symptom and referral action so the reason for withholding the protocol prescription is clear. A case may offer several plausible actions; prioritize the one the protocol directs for the patient's facts. Do not convert an assessment into a diagnosis beyond the pharmacist's stated authority.

Worked example: A hypothetical protocol allows a pharmacist to prescribe medicine X after a screening questionnaire but requires referral if the patient reports a listed warning symptom. The patient completes the questionnaire and reports that symptom. The pharmacist records the response, explains the need for referral, and does not issue medicine X under the protocol. Completing the questionnaire does not override its referral branch.

Watch the distinction: Passing through the screening process does not mean the patient passed its criteria. A referral trigger changes the required action and blocks prescribing under that pathway.

21. Allergies in prospective review

An allergy alert starts an investigation, not an automatic rejection. Ask which drug caused the reaction, what happened, when it happened, and whether treatment was needed. Anaphylaxis, a mild rash, and nausea carry different implications; nausea may be an adverse effect rather than an immune reaction. Compare the implicated drug with the proposed medicine, including active ingredients and clinically relevant class relationships. Check whether the record describes a confirmed reaction or an uncertain patient recollection. If a serious reaction could recur, hold dispensing while clarifying the history and discussing an alternative with the prescriber. Record the facts learned, the decision, and any change to therapy. A computer alert helps locate a risk, but the pharmacist must determine whether that risk applies to this patient. Try this sequence in MPJE South Dakota practice questions.

Worked example: A patient reports anaphylaxis after taking Drug A, and a new prescription is for Drug B in the same class. The pharmacist confirms that the earlier reaction involved breathing difficulty and emergency treatment, then holds Drug B. After discussing the history, the prescriber orders an unrelated alternative. The pharmacist documents the reaction and change before dispensing the alternative; simply clearing the alert would leave the risk unresolved.

Watch the distinction: A shared drug class does not prove every member will cause the same reaction. It signals a need to assess the specific drugs and reaction before dispensing.

22. Interactions and therapeutic duplication

An interaction alert or apparent duplication becomes useful only when placed beside the patient's actual regimen. Compare active ingredients, doses, routes, intended start dates, and whether an older prescription remains in use. Two brand names can conceal the same ingredient, while two drugs in one class may sometimes be deliberately combined. For an interaction, consider the likely harm, timing, patient factors, and whether a dose change, separation, laboratory monitoring, or another medicine would address it. Ask the patient about actual use and clarify uncertain intent with the prescriber. Resolve the finding before release when the potential harm is material, and record the response. Updating the medication list matters: leaving a replaced prescription active can generate future duplicate fills and misleading alerts even after today's decision is correct.

Worked example: A patient presents a new brand-name prescription, but the profile shows a different brand containing the same active ingredient. The patient thinks both should be taken. The pharmacist holds the new fill and calls the prescriber, who confirms the new product replaces the old one. The pharmacist inactivates the old prescription, counsels the patient to stop it, and records the clarification.

Watch the distinction: Two active records do not necessarily mean two intended therapies. Treating the alert as proof of an error without checking the switch could lead to the wrong instruction.

23. Dose and quantity review

Dose review connects the written directions to the product strength, quantity, and intended treatment period. First calculate units per administration, then administrations per day, then daily drug amount. Multiply units per day by the number of days to find the needed quantity. If directions are variable, such as a taper or use as needed, calculate from the stated schedule and identify what cannot be inferred. Compare the result with the prescribed quantity, usual clinical context, and any documented change in therapy. A mismatch may reflect a quantity error, incorrect directions, or a deliberately shorter initial supply. Do not silently choose one interpretation. Obtain the prescriber's intended regimen when it affects safe use, then document the clarification and ensure the label, quantity, and patient instructions agree.

Worked example: Directions specify two 5 mg tablets three times daily for 10 days. Each dose is 10 mg; three doses give 30 mg per day. The patient needs six tablets per day, or 60 tablets for 10 days. The written quantity is 30 tablets, enough for only five days at those directions. The pharmacist clarifies whether the quantity or regimen should change before dispensing.

Watch the distinction: Dividing 30 tablets by 10 days suggests three tablets daily, but that contradicts the written six-tablet daily regimen. Quantity alone cannot establish the intended dose.

24. Counseling on a new therapy

Counseling on a new prescription should make safe use possible for this particular patient. Confirm what the patient believes the medicine is for, then explain the prescribed schedule, route, technique, expected benefit, important precautions, and what to do about a missed dose or a concerning effect when those points matter. Prioritize information that could change how the patient takes it. Demonstration and teach-back can reveal misunderstandings that a leaflet will miss, especially with inhalers, injections, or complex schedules. Address language, hearing, and health-literacy barriers through an effective communication method. If a caregiver will administer the medicine, include that person when appropriate. Record a clinically significant intervention and any applicable counseling documentation. The legal offer of counseling and the clinical content of counseling are separate questions; both deserve attention.

Worked example: A patient calls a newly prescribed maintenance inhaler a rescue medicine. The pharmacist explains that the prescribed inhaler is for scheduled use and checks which medicine the patient has for sudden symptoms. After demonstrating the prescribed device technique, the pharmacist asks the patient to show it back and describe when each inhaler is used. The patient corrects the mix-up before leaving.

Watch the distinction: Handing over a leaflet may convey written facts, but it does not show whether the patient can use the device or has confused maintenance treatment with rescue treatment.

25. Counseling at refill or delivery

Refill counseling depends on the applicable South Dakota provision and the facts of the refill. Look for a changed strength, directions, formulation, or patient condition, even when the computer calls the order a refill. A dose change can create confusion if the patient still has the earlier supply at home. Delivery adds a communication problem: a package insert cannot answer a patient-specific question at the handoff. When a case requires an offer of pharmacist counseling, arrange a practical route for direct contact, such as a pharmacist call or a clearly available live contact method, and document the offer and outcome as the stated rule requires. Verify that the delivered label reflects the current regimen. Counseling can also uncover use of the old dose, an adverse effect, or an access barrier that needs a separate intervention.

Worked example: A delivered refill changes from one tablet daily to two tablets daily. The case rule requires a pharmacist counseling offer for a changed regimen. The pharmacy arranges a pharmacist call before delivery and documents the patient's response. During the call, the patient reports an old bottle at home; the pharmacist explains which directions now apply and confirms the new label matches the changed order.

Watch the distinction: A refill label and generic leaflet do not necessarily satisfy a required counseling offer when the regimen changes. The patient needs a way to discuss the change with a pharmacist.

26. Generic substitution

Generic substitution is a sequence of checks, not a price-based choice. Identify the prescribed brand and proposed generic, then determine whether the proposed product meets the applicable therapeutic-equivalence condition for that prescription. Check the order for a valid prescriber restriction and apply any patient communication or consent condition stated in the governing South Dakota rule. Record the product actually dispensed and any required notice so the prescriber, patient, and later pharmacist can trace the change. A different manufacturer or appearance can confuse patients who have remaining tablets, so explain the active ingredient and how to avoid taking both products. Distinguish substitution from changing the prescribed drug, strength, dosage form, or directions; those changes generally call for separate authority. The broader MPJE study guide provides related practice with these distinctions.

Worked example: A brand prescription has no prescriber restriction. The available generic meets the therapeutic-equivalence condition in the case rule, which also requires patient notice and a dispensing record. The pharmacist explains the different appearance, supplies the generic, and records its identity and the notice. If the prescriber had made a valid prohibition under that rule, the pharmacist could not use this substitution pathway.

Watch the distinction: A lower price does not establish that a product is substitutable. The pharmacist must verify the applicable equivalence standard and any prescriber, patient, and record conditions.

27. Biologic interchange

A biosimilar is a biologic product shown to be highly similar to its reference product under the federal approval framework. An interchangeable designation adds the federal basis for pharmacy-level substitution, subject to state law. Therefore, first identify the reference product and the exact proposed product; similar names or the word “biosimilar” alone do not establish interchangeability. Next check the South Dakota rule supplied in the case for prescriber restrictions, patient communication, prescriber notification, and product-record duties. Preserve the specific product identity because biologics may have distinct names and lot information relevant to follow-up. If the proposed product lacks interchangeable status, obtain a new prescriber decision instead of treating it as an ordinary pharmacy substitution. Even an interchangeable product cannot be substituted if an applicable restriction or condition blocks the transaction.

Worked example: A prescription names a reference biologic. The pharmacy has a less expensive biosimilar, but the case states that it has no interchangeable designation. The supplied South Dakota rule permits pharmacy substitution only for interchangeable products. The pharmacist therefore does not make the swap. The pharmacist can contact the prescriber to request a new prescription for the biosimilar and document the resulting decision.

Watch the distinction: Biosimilar approval and interchangeable designation are distinct. Assuming every biosimilar can be substituted at the pharmacy skips the federal designation and applicable state communication rules.

28. Patient information and disclosures

Start a disclosure question by identifying who wants the information and why. Federal health-information rules permit many disclosures for treatment, payment, and health care operations, but the permitted purpose does not justify sending an entire record when only a smaller set is needed; apply the minimum-necessary rule where it governs. Treatment disclosures and a patient's own access request have different treatment under that rule, so avoid applying one blanket limit to every request. Verify the requester and destination, use an appropriate secure channel, and check whether another law or valid authorization changes the result. A patient's right to access their information is separate from an employer's desire to review it. Document unusual disclosures and resolve uncertainty before releasing sensitive records. In a South Dakota case, apply any additional confidentiality provision given alongside the federal rule.

Worked example: A payer asks for the prescription details needed to adjudicate a claim. That request may fit payment activity, so the pharmacy supplies the relevant claim information through its authorized channel. An unrelated employer then requests the patient's complete medication history. Employment interest alone supplies no valid basis in the case, so the pharmacist withholds the history unless an applicable authorization or other legal basis is established.

Watch the distinction: Because a payer may receive information for payment, it does not follow that any third party may receive the whole profile. Recipient, purpose, and amount disclosed each matter.

29. Corresponding responsibility

A pharmacist dispensing a controlled substance has a professional duty to address signs that a prescription may not be legitimate. Begin with the order's formal requirements, then compare the medicine, directions, patient account, prescriber information, and available history for contradictions. A red flag calls for reasonable inquiry, not an automatic accusation or an automatic fill. Contact the prescriber through a verified channel when needed, ask focused questions, and evaluate whether the answers resolve the concern. Record the facts, contacts, and final decision. If the concern remains unresolved, do not dispense merely because the prescription arrived through a compliant electronic system. A valid transmission establishes how an order was sent; it cannot establish that every clinical or legitimacy concern has been answered. The DEA Diversion Control Division is a federal resource for controlled-substance matters.

Worked example: An electronic controlled prescription lists one tablet daily, but the patient says the prescriber instructed three daily. The pharmacist pauses dispensing and calls the prescriber using a verified office number. The prescriber confirms one daily and says no change was authorized. The pharmacist documents the call, counsels the patient on the confirmed directions, and dispenses only under the resolved order if no other concern remains.

Watch the distinction: An electronic signature or complete set of fields does not resolve a conflicting patient account. The pharmacist must investigate the discrepancy and use judgment before dispensing.

Reference: [1]

30. Emergency continuity of therapy

An emergency-supply case turns on the precise authority supplied, the patient's need, and the medicine involved. Identify whether interruption would create the kind of risk described in the provision, whether the medicine is eligible, and whether a prescriber contact attempt is required. Then determine the permitted amount from that provision; a general desire to maintain therapy cannot create an unstated quantity allowance. Check whether the existing prescription or another lawful route provides continuity before using an exception. Record the reason, contact attempt, product, quantity, directions, and any required follow-up. Explain to the patient that the supply bridges a specific gap and how to obtain a continuing order. Controlled substances or other restricted products may have separate rules, so do not carry an emergency exception from one drug category into another.

Worked example: A hypothetical case rule permits up to three days of an eligible medicine when abrupt interruption poses a stated risk and the prescriber cannot be reached. The patient takes one tablet twice daily, has no remaining tablets, and meets those conditions. The pharmacist attempts contact and documents it, then supplies six tablets: two per day times three days. The pharmacist records the rationale and explains the need for a continuing prescription.

Watch the distinction: Calling a supply “emergency” does not create authority. Eligibility, the stated risk, contact conditions, amount, and documentation all come from the applicable provision.

31. Prescriber authority

A prescriber's professional license is the starting point, not the entire authority analysis. Identify the credential and its status, then ask whether the prescriber's scope covers this medicine, patient, and purpose. Some authority may depend on a practice setting, supervising arrangement, protocol, or patient relationship described in the case. For a controlled medicine, also check the separate controlled-substance authority relevant to the transaction. Match the actual order to those conditions rather than relying on a familiar title or a valid signature. If the scope is unclear, seek clarification from the prescriber or an authorized source before dispensing. Record the resolution and any replacement order. Do not rewrite an out-of-scope order as though the original prescriber possessed authority; a different authorized prescriber must make the prescribing decision when required.

Worked example: A clinician has an active license, but the case provision limits prescribing to patients within a defined practice area. The order concerns a patient and purpose outside that area. The pharmacist holds it, confirms the scope facts, and contacts the clinician. Because the supplied authority does not cover this order, the pharmacist seeks a lawful order from a prescriber with the necessary authority before dispensing.

Watch the distinction: A current license proves the person holds that credential. It does not establish authority to prescribe every drug for every patient or purpose.

32. Required prescription information

A prescription must convey enough information to identify the patient, authorized prescriber, product, and intended use, along with any elements required for that drug and transmission route. Review the drug name, strength, dosage form, directions, quantity, and dates in the context of the governing provision. A missing element may be a clerical omission that an authorized clarification can resolve, or it may leave the intended treatment unknown. Do not infer directions from a prior fill, a typical regimen, or a package size when the current order is silent. Contact the prescriber through an appropriate channel, confirm the intended instruction, and record who supplied the clarification and when. Controlled-substance prescriptions may restrict how particular elements can be corrected, so apply the specific rule before editing. The final label should accurately reflect the authorized order.

Worked example: An order names a patient, prescriber, drug, and 10 mg strength but contains no directions. The pharmacist cannot know whether the patient should take one tablet daily or another regimen. After contacting the prescriber, the pharmacist confirms one tablet by mouth each evening and documents the clarification. Only then does the pharmacist prepare the label and dispense the confirmed quantity.

Watch the distinction: A familiar drug dose is not a substitute for the prescriber's intended directions. Filling in a blank from customary use risks creating an order the prescriber never made.

33. Federal and state rule conflicts

A pharmacy transaction can be governed by federal law and South Dakota law at the same time. Identify the precise act first: issuing, transmitting, filling, refilling, transferring, or recording a prescription. Then list the conditions each applicable rule places on that act. A federal permission does not erase a stricter state condition, and a state permission cannot authorize what federal law prohibits. Apply the requirements together when possible; if one route fails, consider another lawful route rather than treating the order as permanently unusable. Pay attention to dates because amendments and temporary provisions can change which text governs a transaction. When a question supplies the provisions, use their wording and effective dates. A related North Dakota MPJE guide can help you practice keeping neighboring state rules separate.

Worked example: A hypothetical federal provision permits a particular electronic transmission for a drug. A South Dakota provision supplied in the case requires a different form for that setting, and both apply on the service date. The pharmacist cannot fill from the electronic transmission alone. The prescriber sends the form required by South Dakota law; the pharmacist verifies the remaining federal and state conditions before dispensing.

Watch the distinction: “Federal law allows it” is incomplete when an applicable state rule adds a condition. Equally, a state rule cannot override a federal prohibition.

34. Ambiguous and conflicting directions

Conflicting directions are evidence that the intended order has not been established. Compare every part of the prescription, including structured fields, free-text notes, quantity, and prior regimen, but do not vote among them or assume the latest-looking entry wins. Determine whether the conflict changes dose, frequency, duration, or patient safety. Ask the prescriber for the intended directions through an authorized channel, then document the clarification and apply any rule governing who may amend the record. Update the label and days' supply calculation to match the confirmed order. If the response remains ambiguous, seek further clarification before release. A patient's memory can help locate the problem but cannot, by itself, authorize a change to the prescriber's order. Preserve the audit trail so a later pharmacist can see why the final directions differ from an earlier field.

Worked example: The structured field says one tablet daily, while a note says two tablets daily. The pharmacist contacts the prescriber, who confirms two tablets daily and a 30-day treatment period. That requires 60 tablets, not 30: two per day times 30 days. The pharmacist records the confirmation, corrects the order through the permitted process, and labels the 60-tablet supply for two daily.

Watch the distinction: Choosing the structured field because it looks more formal, or choosing the note because it looks newer, substitutes guesswork for the prescriber's confirmed intent.

35. Altered or suspect prescriptions

An overwritten quantity, inconsistent ink, unusual formatting, or a mismatch with the prescriber's known practice can signal alteration, but a visual cue alone does not prove fraud. Hold the prescription while establishing its origin and intended terms. Use an independently verified prescriber contact, rather than a phone number written on the questionable paper, and ask about the disputed element. Confirm the patient's identity and any other facts needed to assess legitimacy. Record who answered, what was confirmed, and the disposition of the order. If the prescriber confirms a different quantity, follow the applicable correction or replacement-order rules before dispensing. If authenticity remains unresolved, do not release the medicine. The goal is to prevent dispensing on an unauthorized change while preserving access to treatment through a valid order.

Worked example: A paper prescription's quantity appears changed from 10 to 100 tablets. The pharmacist finds the prescriber's number in an independent directory and calls the office. The prescriber confirms an order for 10 and denies authorizing 100. The pharmacist does not dispense 100, documents the verification, and obtains the valid form or correction required for a 10-tablet dispense.

Watch the distinction: Calling the number printed on a suspect prescription may reach the person who altered it. Independent verification and documentation are needed before treating the disputed quantity as authorized.

36. Electronic controlled prescriptions

Electronic prescribing of controlled substances has requirements beyond sending drug information over the internet. The federal framework addresses approved application functions, prescriber authentication and signing, transmission, and pharmacy receipt and retention. Evaluate whether the item actually arrived through a compliant prescribing system as an electronic prescription, rather than as a scan, email attachment, or message containing an image of a signed page. An image may still have a separate legal role under a rule for faxed or written orders, but it does not become a compliant electronic controlled prescription merely because it was delivered digitally. Check the drug's schedule and any applicable South Dakota condition before dispensing. If the electronic route fails, obtain an order through a lawful alternative route for that transaction. The DEA's controlled-substance resources provide the federal context.

Worked example: A prescriber emails a photograph of a signed Schedule II prescription to the pharmacy. The image arrived electronically, but the case states it did not pass through a compliant electronic controlled-prescribing system. No exception in the case lets that image serve as the original order. The pharmacist holds the fill and requests a lawful prescription through an approved route before dispensing.

Watch the distinction: “Received on a computer” does not mean “valid electronic controlled prescription.” The transmission and signing process, as well as the prescription's contents, must meet the governing conditions.

Reference: [1]

37. Oral, written, and faxed orders

Classify an order by how it was actually communicated: an oral order spoken to an authorized recipient, a physical written order, a faxed image, or a compliant electronic prescription. The permissible route can differ by drug schedule and circumstance. For a Schedule II prescription, a fax generally is not the original dispensing authority unless a specific exception applies; an emergency oral order also has its own conditions. Do not convert one route into another by printing a fax or scanning paper into the pharmacy system. Identify the prescriber, patient, drug, and setting, then test the route against both federal and applicable South Dakota rules. If the route fails, obtain the proper order and document any authorized clarification. A fax may communicate useful information while still being insufficient as the legal basis for dispensing.

Worked example: A pharmacy receives a faxed Schedule II prescription for routine outpatient treatment. The case provides no exception allowing the fax to serve as the original. Printing it does not change its route. The pharmacist uses the fax to identify the prescriber and patient, requests a lawful original or compliant electronic prescription, and waits for that authority before dispensing.

Watch the distinction: A printed fax may look like a written prescription, but its legal classification depends on how it was transmitted. Appearance does not create an exception.

Reference: [1]

38. Controlled-substance schedules

Determine the drug's current federal schedule before applying a controlled-prescription rule. Schedule classification affects whether a prescription may be refilled, which ordering process applies to pharmacy stock, and which records are needed. A product's name, dosage form, or similarity to another drug is unreliable evidence of its schedule; use the classification supplied in a case or an authoritative current listing. Also check whether a product-specific exception or a South Dakota rule changes the transaction's requirements. Once classified, apply the rule for that schedule to the exact act being considered. For example, a refill question is different from a partial-fill question even when both concern the same prescription. The DEA Diversion Control Division publishes federal controlled-substance schedule resources; a case may still supply a schedule and date that govern its own facts.

Worked example: A case identifies Drug A as Schedule II and a similarly named Drug B as Schedule IV. Each has a prescription with one refill written on it. The pharmacist cannot use Drug B's refill pathway for Drug A: the Schedule II refill notation is ineffective. Drug B's refill is evaluated under the separate rules applicable to Schedule IV on the transaction date.

Watch the distinction: Grouping all controlled medicines under one refill rule loses the schedule distinction. Confirm the exact product's classification before applying a permission or prohibition.

Reference: [1]

39. Controlled-substance refills

A refill is another dispensing under the same prescription authorization, so begin with the drug's schedule and the status of the original prescription. Federal law prohibits refilling a Schedule II prescription; a prescriber-written refill count cannot override that prohibition. Schedules III and IV have federal limits on refill number and time, while Schedule V follows its applicable federal and state conditions. For any permitted refill, also check the authorized count, elapsed period, prescription status, remaining quantity, and any tighter South Dakota rule in the case. Do not disguise a new supply as a partial fill or transfer when the relevant authority has ended. If further Schedule II treatment is intended, the prescriber must issue new lawful authority. Record the dispensing against the correct prescription so the history cannot support duplicate supply.

Worked example: A Schedule II prescription for 30 tablets is filled in full and bears “one refill.” The patient returns requesting another 30 tablets. The pharmacist cannot use that notation because Schedule II prescriptions are not refillable; a new lawful prescription is needed. A separate Schedule IV prescription with a written refill is assessed under its own schedule's limits and any applicable South Dakota condition.

Watch the distinction: A prescriber's refill notation cannot make a prohibited Schedule II refill valid. The pharmacist must classify the drug before relying on a refill count.

Reference: [1]

40. Schedule II partial fills

A partial fill supplies less than the prescribed amount while leaving a possible balance, but the reason for the partial fill controls important rules. Distinguish inadequate pharmacy stock from a patient or prescriber request and from other special circumstances described in a case. For a Schedule II order, record the amount supplied, date, reason, and remaining balance, then apply the completion period tied to that reason and the governing law. Calculate the balance from the original authorized quantity, subtracting every amount already dispensed. Do not treat the balance as an ordinary refill; it remains linked to the original prescription and its applicable completion conditions. If the window closes or another condition fails, obtain new lawful authority before supplying more. Communicate clearly with the patient about what was supplied and whether a balance may still be obtained.

Worked example: A Schedule II prescription authorizes 30 tablets, but the pharmacy has only 12 because of a stock shortage. The pharmacist dispenses 12 and records the shortage, date, and amount. The possible balance is 18 tablets: 30 minus 12. Before supplying any of those 18, the pharmacist checks the stock-shortage completion window given in the case and records the additional amount, if permitted.

Watch the distinction: The 18-tablet balance is not a refill. Its availability depends on the reason for partial filling and the associated completion and record rules.

Reference: [1]

41. Transfers between pharmacies

Start by identifying what the patient wants moved: an unfilled prescription, a remaining refill, or a prescription already exhausted. Transfer rules can differ by drug schedule, prescription format, and whether any dispensing has occurred. Confirm that the receiving pharmacy is authorized to fill it and that the particular transfer is permitted under the governing federal and South Dakota provisions. The record must show what authority remains after prior fills, including the original directions, refill authorization, and relevant dispensing history. The transferring pharmacy must change its own record so the same authority cannot be used twice. The receiving pharmacist should reconcile the transferred details with the patient's account and resolve discrepancies before dispensing. A patient's choice of pharmacy does not create a new refill or cure an invalid original prescription.

Worked example: A prescription authorized three refills. The first fill and two refills are documented, leaving one refill. The patient asks Pharmacy A to send it to Pharmacy B, then asks both pharmacies to fill it. Assuming this transfer is permitted, A communicates one remaining refill and marks its record transferred. B may use that one refill; A cannot also dispense it.

Watch the distinction: A transfer is not a copy that leaves two usable prescriptions. If both pharmacies retain an active refill, the same authorization could be dispensed twice.

42. Emergency Schedule II orders

An emergency oral Schedule II prescription is a narrow federal exception. Test the facts in sequence: Is immediate administration needed for proper treatment? Is an appropriate alternative available? Can the prescriber provide the ordinary required prescription before dispensing? The prescriber must communicate the order directly to a pharmacist, and the pharmacist must establish that it comes from an authorized prescriber. Dispense only the quantity adequate for the emergency period, record the oral order, and track the required follow-up prescription and any action required if it does not arrive. A patient saying the situation is urgent does not establish every legal condition. The DEA Diversion Control Division is the federal issuer for controlled-substance resources; a case involving South Dakota practice still requires checking applicable state conditions.

Worked example: A prescriber calls about a patient who needs immediate treatment. The case states that no appropriate alternative is available and the ordinary prescription cannot reach the pharmacy in time. The pharmacist verifies the caller, records the oral order, and dispenses only the stated emergency quantity. The pharmacist then monitors receipt of the required follow-up prescription and acts under the governing rule if it is missing.

Watch the distinction: A telephone order does not become an ordinary Schedule II prescription because the prescriber promises paperwork later. The emergency conditions and follow-up duties must actually be met.

Reference: [1]

43. Labels and protective packaging

Review the finished prescription as the patient will receive it. Match the label to the authorized order, including patient identity, drug, strength, directions, quantity, and any other information required by the applicable rule. Directions should communicate a usable regimen; an internal abbreviation that a patient might misunderstand needs correction. Next examine the container. Federal child-resistant packaging requirements generally apply to covered outpatient prescription drugs unless an exemption or valid waiver applies. Determine whether a request for easier opening came from someone authorized to make it, what prescriptions it covers, and how the pharmacy must document it. Packaging also has to protect the product itself: a waiver of child resistance does not excuse unsuitable light or moisture protection. Resolve a label or container defect before release, even when the clinical review is complete.

Worked example: A patient asks for an easy-open container for today's prescription. The pharmacist confirms that the request is valid, documents its stated scope, and uses a container suitable for the drug. A later prescription is evaluated against that documented scope and the applicable rule. The first request is not automatically treated as covering every future medicine.

Watch the distinction: A correct drug in a sealed vial is not necessarily ready to dispense. The label may be misleading, or the container may fail an applicable packaging requirement.

44. Prescription monitoring data

A prescription monitoring program serves several distinct functions. Reporting places qualifying dispensing events into the database; querying lets an authorized user review information for a permitted purpose; disclosure sends information to someone else. Authority for one function does not establish authority for the others. In a controlled-prescription review, compare the report with the patient history, current order, and any explanation for apparent overlap. A record may be delayed or contain an error, so an unexpected entry is a reason to investigate, not automatic proof of misconduct. If the supplied South Dakota provision mandates a query or report, identify the covered transaction, responsible person, timing, and exceptions. Keep the report within the permitted clinical or regulatory use, restrict access to authorized personnel, and record the action required by the case rule.

Worked example: A pharmacist queries the monitoring database while reviewing a controlled prescription. It shows a recent similar fill, so the pharmacist asks the patient and prescriber about a possible replacement order before dispensing. An employer then requests the full report. The clinical query does not authorize that disclosure; the pharmacy withholds it unless a separate legal basis is established.

Watch the distinction: A monitoring report is neither a verdict nor a public record. Treating every overlap as diversion, or forwarding the report because it was lawfully accessed, skips separate legal and clinical checks.

45. Returns, reuse, and distribution

Trace the medicine's custody before deciding what a return means. An uncollected prescription may still be under pharmacy control, allowing the pharmacy to reverse its dispensing and billing records and evaluate whether the product can safely return to stock under applicable rules. Once medication has gone home with a patient, the pharmacy usually cannot verify its storage or integrity merely from an intact-looking seal. A claim reversal changes the financial record; it does not prove the product is saleable. Identify any specific return or reuse exception, including its conditions for packaging, custody, and documentation, before considering redistribution. If no exception applies, segregate the returned item from saleable stock and use an appropriate disposal route. Controlled substances require their own handling and record process. Keep patient credit, inventory status, and physical disposition as separate decisions.

Worked example: A patient takes home a sealed bottle and returns it the next day, unopened. Staff reverse the insurance claim, then check whether any applicable rule permits reuse after patient custody. None is supplied, so they do not put the bottle back on the shelf. They segregate it and document its disposition through the appropriate process.

Watch the distinction: An unopened package is not proof of continuous pharmacy control. The fact that a claim can be reversed does not make the returned medication suitable for another patient.

46. Pharmacy permit categories

A facility's permit must fit both its location and what it actually does. Begin with the operator and premises, then classify the activity: institutional distribution, outpatient dispensing, community service, specialty service, or another category described by the governing South Dakota provision. A pharmacist's individual license does not replace the facility's permit. A permit for one setting may carry limits on patients served, storage, staffing, or delivery methods; adding a service can therefore change the required authority. Check whether the permit is effective for the site and activity on the service date, not simply whether an application is pending. For a case, separate the permission to possess stock from permission to dispense to a particular class of patients. MPJE South Dakota practice questions can help you rehearse that classification sequence.

Worked example: A hospital pharmacy has a permit that, in the case, covers inpatient medication service only. It plans to fill take-home prescriptions for the public starting Monday. Because that is a new activity outside the stated permit, it must obtain the required outpatient authority before Monday's first public dispense. Employing licensed pharmacists does not expand the facility permit.

Watch the distinction: A permitted pharmacy is not automatically permitted to perform every pharmacy service. Match the permit's stated activity and premises to the transaction being evaluated.

47. Nonresident pharmacy activity

When an out-of-state pharmacy serves a South Dakota patient, evaluate the transaction from both locations. The home-state license establishes authority in the home jurisdiction, while South Dakota may require a nonresident permit and conditions for serving its residents. Mailing a finished prescription is still a pharmacy service directed to the patient's state. Read the supplied provision for covered activities, permit status, designated contact or pharmacist responsibilities, record access, patient communication, and complaint handling. Distinguish the pharmacy sending a prescription to another pharmacy from the pharmacy actually dispensing and shipping medication to the patient. Also identify who holds any federal controlled-substance registration needed for the activity. For jurisdiction comparisons, a Colorado MPJE guide illustrates why another state's requirements cannot simply be substituted for South Dakota's.

Worked example: A pharmacy licensed in another state begins mailing filled prescriptions to South Dakota addresses. The hypothetical South Dakota rule requires a nonresident permit before that service begins. The pharmacy's home license remains relevant but does not satisfy the South Dakota condition. It obtains the permit, then follows the case's patient-contact and record-access duties for its mailed prescriptions.

Watch the distinction: Physical distance does not remove the destination state's interest in the service. A valid home-state license alone does not answer a South Dakota nonresident-permit question.

48. Opening and relocation

A pharmacy relocation changes the premises where regulated stock, records, staff, and patients meet. Test the old site's authority separately from the proposed new site's authority. A permit may be tied to a specific address, and the supplied South Dakota rule may require an application, inspection, notice, or approval before dispensing starts at the new location. Map the transition date: when the old site stops dispensing, when stock moves, when the new site becomes authorized, and how prescriptions remain accessible. Secure controlled stock during transport and preserve an auditable movement record. If approval is pending, moving equipment or inventory does not itself start dispensing authority. Likewise, the old site's permit does not automatically follow the owner across town. The key question is which premises was authorized at the moment each prescription was dispensed.

Worked example: A pharmacy plans to move stock on Friday and open at its new address Saturday. The case rule requires approval of the new premises, but approval will not be effective until Monday. Saturday dispensing at the new site is unauthorized under that rule. The pharmacy keeps stock secure and arranges lawful continuity until Monday rather than using its old-address permit.

Watch the distinction: A relocation is more than changing the address printed on labels. The new premises may need its own approval before staff may dispense there.

49. Ownership change and closure

An ownership change affects who holds legal responsibility for the operation. Determine whether the governing South Dakota provision permits continuation under an existing permit or requires a new one, and identify the effective handoff date. Then trace four assets separately: prescription records, patient access, saleable inventory, and controlled stock. A business sale document does not itself transfer a pharmacy permit or federal registration. If the site closes, patients still need a lawful way to obtain their prescription information, and records must remain retrievable for the applicable period. Controlled substances require documented transfer or disposal through an authorized route. Public notice, board notice, or record-custodian information may be required by the supplied case rule. A good answer assigns each duty to the seller, buyer, or record custodian instead of assuming the closing date ends all obligations.

Worked example: An owner sells a pharmacy effective June 1, but the case requires the buyer's own permit and it is not yet effective. The buyer cannot dispense under the seller's permit on June 1. The parties secure stock, arrange lawful controlled-stock transfer, and designate accessible custody for patient records until the buyer can operate or patients transfer elsewhere.

Watch the distinction: Buying the business does not automatically confer its regulatory credentials. The parties must resolve operating authority and the continuing custody of stock and records.

50. Authorized purchasing and tracing

A low price is not a substitute for a lawful supply chain. Before accepting prescription drug stock, identify the seller's role and confirm it is an authorized trading partner for the transaction. Then match the physical product to the transaction information and any required tracing documentation: product identity, lot, quantity, source, and movement should make sense together. Unexplained gaps, damaged packaging, or inconsistent identifiers call for quarantine and investigation before stock is made available for dispensing. The federal drug supply-chain framework also distinguishes tracing from product quality; complete paperwork does not make a visibly suspect package safe. Document receipt and preserve records in retrievable form for the applicable period. Multistate pharmacy jurisprudence practice benefits from treating authorization, traceability, and physical condition as three separate checks.

Worked example: A wholesaler offers ten discounted cartons. Its authorization is unverified, and the case requires transaction information that the seller cannot provide. The pharmacy does not place any carton into saleable stock. It verifies the seller, reconciles each carton with the required information, and investigates the gap before accepting or dispensing the lot.

Watch the distinction: A plausible invoice does not establish that the seller is authorized or that the product can be traced. Both the trading partner and the shipment need scrutiny.

51. Suspect product and recalls

The first operational step for a suspect product or affected recall lot is to stop its movement. Separate it physically or electronically from saleable stock so a normal filling workflow cannot select it. Read the notice precisely: product, strength, package, lot, expiration, and distribution scope can all matter. Match those identifiers to on-hand stock, purchase records, transfers, and dispensing history. The response may include notifying affected patients or facilities, returning product, or documenting destruction, depending on the notice and governing requirements. An authenticity concern also requires investigation of the source and transaction path before release. Do not infer that all adjacent packages are affected, but do not release an apparently unaffected package until its identity is confirmed. Record what was located, held, dispensed, and ultimately resolved so the action is auditable.

Worked example: A recall names lot B17 of a particular strength. The shelf holds four B17 packages and six B16 packages. Staff quarantine the four B17 packages and search dispensing records for B17 units already supplied. They confirm the six B16 identifiers before leaving them available, then follow the recall's instructions for affected stock and patient follow-up.

Watch the distinction: A recall is not resolved by removing visible packages from one shelf. Dispensed units, other storage locations, and the exact lot identifiers also need review.

52. Storage and temperature excursions

A temperature alarm describes an exposure, not the final usability decision. Establish which products were present, the labeled storage condition for each, the highest or lowest recorded temperature, and the duration of exposure. Use a calibrated or otherwise reliable record where required; a single current reading cannot reconstruct an overnight event. Quarantine affected stock to prevent dispensing while obtaining product-specific stability guidance and assessing whether transport or repeated excursions add exposure. Record the decision and its supporting source for each product or lot. If the evidence cannot support continued use, dispose of the product through the appropriate route. The reasoning must distinguish a brief excursion from a prolonged one without inventing a universal safe range. For vaccines and other sensitive products, a return to normal refrigerator temperature does not reverse possible potency loss.

Worked example: A refrigerator alarm shows an overnight excursion above the labeled range. Two different medicines were inside. Staff isolate both, record the temperature trace and time window, and seek stability guidance for each product. Guidance supports continued use of one lot but not the other, so only the supported lot returns to stock; the other remains quarantined for disposition.

Watch the distinction: A refrigerator cooling back down says nothing conclusive about what happened to the medicine during the excursion. Product-specific exposure evidence controls the decision.

53. Controlled-substance ordering

Controlled-substance purchasing begins with the drug's schedule and the pharmacy's authority to acquire it. Schedule II orders use the applicable federal order-form or electronic ordering process; orders for other controlled schedules follow their own documentation rules. On receipt, compare the supplier's shipment with the order and invoice, recording what physically arrived rather than copying the expected quantity. Investigate shortages, overages, damage, and suspicious packaging before completing the transaction or making stock available. Maintain the required order and receipt records so the chain from supplier to inventory is clear. A mismatch may be a shipping error, a recording error, or a diversion concern; evidence determines which. The DEA Diversion Control Division provides federal controlled-substance ordering and reporting resources, while the case's South Dakota provisions may add duties.

Worked example: A Schedule II order and invoice show ten bottles, but the sealed shipment contains nine. Staff record nine received, leaving a one-bottle discrepancy. They check the packing materials and contact the supplier, preserving the order and receipt evidence. They do not enter ten into inventory or close the discrepancy merely because the invoice says ten.

Watch the distinction: The ordered quantity is not the received quantity. Recording an absent bottle as stock hides a discrepancy and makes later inventory reconciliation unreliable.

Reference: [1]

54. Controlled inventory records

A controlled inventory is an accounting trail tied to physical stock. Choose a defined start point and unit of measure, then calculate expected stock as opening count plus receipts and valid returns, minus dispensing, transfers, and documented destruction. Compare that result with the physical count for the same drug, strength, package, and location. An unexplained difference calls for checking source documents, transaction timing, unit conversions, and access logs. Do not use an unsupported adjustment simply to make the numbers agree. Required inventories and transaction records may have particular federal and South Dakota formats and retention periods; apply the provisions supplied in the case. Retrievability matters as much as retention: a record that exists but cannot be produced for inspection may fail its purpose. Separate Schedule II records where required by the governing rule.

Worked example: Opening stock is 100 tablets. The pharmacy receives 20 and dispenses 40, with no other documented movements. Expected stock is 100 + 20 - 40 = 80 tablets. A physical count of 77 shows a three-tablet shortage. Staff review receipts, fills, and access records, then document the supported finding rather than entering a three-tablet balancing adjustment.

Watch the distinction: An inventory adjustment is a record of an explained event, not an explanation by itself. Making the balance equal 77 does not identify where three tablets went.

Reference: [1]

55. Discrepancy, theft, and loss

When controlled stock does not reconcile, preserve the original count and investigate promptly. Recount the correct item and package size, then check receipts, dispensing, transfers, returns, destruction records, posting dates, and authorized access. A documented transaction posted to the wrong item can explain an apparent shortage, but a guess cannot. If a discrepancy remains, assess whether facts indicate theft or significant loss under the governing federal and South Dakota reporting provisions. Relevant facts may include the substance, quantity, pattern, circumstances, and risk of diversion; do not invent a universal numerical cutoff. Reporting and internal investigation can both be necessary. Keep the timeline, witnesses, records reviewed, corrective actions, and any reports together so the decision is reviewable. A delayed report cannot be justified merely by leaving an unexplained shortage open indefinitely.

Worked example: Inventory first appears short by 20 tablets. Staff find a documented 20-tablet transfer posted under the wrong strength. After correcting that supported entry, expected and physical counts match, so the apparent shortage is zero. If the transfer record did not explain it, the pharmacy would continue investigating and assess theft or significant-loss reporting duties.

Watch the distinction: Not every discrepancy proves theft, and not every unexplained shortage is a harmless clerical error. Investigate the evidence before classifying and reporting it.

Reference: [1]

56. Dispensing, compounding, and manufacturing

Classify medication preparation by its relationship to a patient, its purpose, scale, and distribution route. Dispensing supplies a finished drug under an authorized prescription. Compounding combines or alters ingredients to produce a preparation for a legitimate clinical need under an applicable patient-specific or other lawful pathway. Manufacturing generally concerns production for broader distribution under a different regulatory framework. Labels such as 'custom' or 'pharmacy made' do not decide the category. Ask whether a named patient or permitted anticipatory basis exists, who receives the product, whether copies of commercially available products are involved, and whether the pharmacy sells unrestricted batches to other businesses. Office-use supply raises its own state and federal questions. The classification determines which authority, quality controls, labeling, and records apply; a lawful patient prescription does not authorize an unrelated wholesale distribution program.

Worked example: A prescriber orders a customized cream for one named patient, and the pharmacy prepares and labels that patient's batch under the case's compounding pathway. The owner then proposes making 500 identical jars for unrestricted sale to clinics. The second plan changes the scale and distribution purpose, so the pharmacy must evaluate manufacturing or distribution authority separately.

Watch the distinction: Preparing a product inside a pharmacy does not automatically make every batch pharmacy compounding. Patient relationship and distribution purpose can change the legal category.

57. Nonsterile compounding controls

A nonsterile compound needs a reproducible formula and a record of what actually happened. Confirm the prescription and clinical purpose, then identify ingredients, strengths, sources, quantities, equipment, mixing sequence, and quality checks. Calculate concentrations in consistent units and state whether percentages are by weight or another basis. Check that the final mass or volume balances after all ingredients are included. The preparation record should connect ingredient lot numbers and quantities to the finished batch and its label. Beyond-use dating must follow the applicable standard and available stability information; it is not simply the earliest ingredient expiration copied onto the label. Review appearance, uniformity, packaging compatibility, and directions before release. A correct arithmetic result does not compensate for an unapproved ingredient, poor mixing, or missing records.

Worked example: A hypothetical formula calls for 150 g of cream containing 2% drug by weight, with no other ingredients. Drug needed is 0.02 × 150 g = 3 g. Base needed is 150 g - 3 g = 147 g. The compounder records both amounts, ingredient lots, checks, and a supported beyond-use assignment.

Watch the distinction: Two percent does not mean 2 g in every batch. Apply the percentage to the final batch mass, then account for every ingredient in that mass.

58. Sterile compounding controls

Sterile compounding requires more than the correct ingredient calculation. Verify that the pharmacy and personnel have authority for the activity, then evaluate the environment, equipment, aseptic technique, component suitability, and required monitoring. A contamination-control failure can invalidate an otherwise accurate preparation because a sterile product enters a high-risk route of administration. Distinguish an in-process deviation from a release criterion failure, and use the case's stated rule to decide whether the batch must be held, investigated, remade, or discarded. The record should connect personnel, components, lot numbers, preparation steps, environmental results, and final verification to each batch. Assign the beyond-use date from the governing standard and supporting stability and sterility conditions. Do not infer sterility from a clear appearance; microbial contamination may be invisible.

Worked example: A batch contains the correct drug concentration and passes its visual check. The case states that an environmental monitoring result must meet a release criterion, and this batch's result fails it. Staff hold the batch, investigate the deviation, and document disposition under that rule. Correct ingredients alone do not permit release.

Watch the distinction: A clean-looking solution is not evidence that aseptic controls succeeded. A failed required release condition remains a failure even when the dose calculation is right.

59. Automated, remote, and central services

Distributed pharmacy systems split a prescription into distinct controlled steps. A central site may process data or verify an order, while another site stocks a cabinet, grants access, and releases medication. Assign a responsible person and record to each step: prescription review, product selection, stocking accuracy, access control, delivery, counseling availability, and error response. Then read the supplied South Dakota authorization to see which tasks may be remote, which require local supervision, and whether the sites need separate permits or agreements. A completed central check does not prove that the correct product was loaded into the remote device. Audit trails should connect the verified order to the product removed and patient served. Technology can move a task, but it does not dissolve the pharmacist's professional judgment or the facility's operational duties.

Worked example: A central pharmacist verifies a prescription for a remote cabinet. The case rule also requires a local pharmacist check when the cabinet is stocked. That check has not been documented, so staff hold release even though the prescription itself is verified. After the stocking check is completed and recorded, the cabinet may be used under the stated arrangement.

Watch the distinction: Remote verification and physical stocking are different controls. Passing one does not establish that the correct medicine occupies the cabinet slot.

60. Records and medication disposal

Record retention is a continuing duty tied to the record type and governing rule, not to whether the storefront remains open. Identify prescription, controlled-substance, compounding, inventory, and transaction records separately; their retention and retrieval requirements may differ. Determine the start date for each applicable period and who will maintain access after relocation, sale, or closure. Electronic records still need integrity, readable format, and a practical way to produce them during the required period. For unusable medication, separate saleable stock from material awaiting return or destruction, then choose a lawful route for the drug category. Controlled-substance disposal has distinct authorization and documentation requirements. Record what was destroyed or transferred, by whom, when, and through which process. Closing the premises does not erase either record custody or accountability for stock.

Worked example: A pharmacy closes while its prescription records remain within the hypothetical retention period. It names an accessible custodian and preserves the records in readable form. Staff segregate expired stock and document disposal through the applicable process, with separate handling for controlled substances. Locking the doors does not end either obligation.

Watch the distinction: Closing a pharmacy does not make its records disposable on the closing date. Retention and lawful medication disposition continue under their respective rules.

Reference: [1]